GOSSAMER BIO INC
GOSSNASDAQTrading Snapshot
- Day Range
- $0.18 – $0.18
- 52-Week Range
- $0.11 – $3.87
- Volume
- $1.64B
- Avg Volume
- $1.88B
- Shares Outstanding
- 488.9M
- Next Earnings
- Sep 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $55M
- Last Q Revenue
- $13M
- P/E Ratio
- —
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-0.78
- Dividend Yield
- —
Why Investors Own GOSS
- ✓High-growth profile — revenue up +36.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About GOSSAMER BIO INC
A company profile for GOSSAMER BIO INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Check out the stocks that are attracting the most attention and driving market activity.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Which stocks are moving before the opening bell on Tuesday?
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD) shares moved
This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts upgraded Grupo Cibest, Lufax, Honeywell, and Gossamer Bio. JBS also received an upgrade. See what analysts think.
Leerink Partners Upgrades Gossamer Bio to Outperform, Maintains Price Target to $1
Leerink Partners analyst Joseph Schwartz upgrades Gossamer Bio (NASDAQ:GOSS) from Market Perform to Outperform and maintains the price target from $1 to $1.